Precision radiation therapy for pancreatic tumors in MEN1 patients

Plain-English translation of NCT05037461 on ClinicalTrials.gov ↗ · Source last updated December 2024 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new treatment called MR-guided radiotherapy (MRgRT) for pancreatic neuroendocrine tumors in patients with MEN1 syndrome. MR-guided radiotherapy uses advanced imaging combined with radiation to precisely target tumors while sparing healthy tissue. The goal is to offer patients a less invasive option than surgery, which can cause significant side effects and complications.

Many MEN1 patients develop multiple pancreatic tumors over their lifetime and currently face a difficult choice: surgery (which can cause lasting health problems) or watchful waiting (which risks the tumor growing and spreading). This trial exists to see if the new treatment can effectively control these tumors without the morbidity associated with surgery, improving quality of life for MEN1 patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with MEN1 syndrome and have pancreatic neuroendocrine tumors
your tumor is between 1 and 3 centimeters in size, or you have smaller tumors showing slow or moderate growth on imaging
your tumor would normally warrant surgery according to your medical team
you are able to undergo MRI imaging without contraindications such as incompatible metal implants or severe claustrophobia
you have not received previous radiation therapy to the upper abdomen

You likely don't qualify if…

you have a tumor larger than 3 centimeters or one showing rapid growth (more than 4 mm per year)
your tumor is causing hormone-related symptoms (with rare exceptions for certain tumor types)
you are currently taking somatostatin analog medications or chemotherapy
you have had peptide receptor radionuclide therapy in the past 12 months
you are pregnant or have metastatic disease elsewhere in your body

What participation looks like

If you qualify, you will receive radiation therapy delivered over 5 treatments across 10–14 days using the MR-Linac machine, which combines MRI imaging with radiation to precisely target your tumor. Treatments are scheduled 2–3 times per week on alternating days. You will need to have imaging scans before treatment to plan your therapy, and the medical team will monitor how your tumor responds after the treatment is complete.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Precision radiation therapy for pancreatic tumors in MEN1 patients

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)